Is Amgen Looking At Sourcing Erythropoietin From Indian Companies?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As pharmaceutical companies the world over gear up for the emerging multi-billion dollar biosimilars opportunity in the U.S., biotechnology major Amgen is said to be looking at sourcing a part of its erythropoietin raw material requirements from Indian companies. Amgen sells the nearly $6 billion blockbuster anemia drug under brand name Epogen